Prot #CRDF-003: A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation

Project: Research project

Project Details

StatusActive
Effective start/end date1/31/241/30/25

Funding

  • Cardiff Oncology, Inc. (Advance Account)